ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Myelodysplastic Syndrome (MDS) Therapeutics Market Research Report 2024
Published Date: August 2024
|
Report Code: QYRE-Auto-19R13960
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Myelodysplastic Syndrome MDS Therapeutics Market Research Report 2023
BUY CHAPTERS

Global Myelodysplastic Syndrome (MDS) Therapeutics Market Research Report 2024

Code: QYRE-Auto-19R13960
Report
August 2024
Pages:72
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Novartis
Celgene Corporation
Otsuka Pharmaceutical Co Ltd
Sandoz Inc
Dr Reddys Laboratories Limited
Pharmascience
Accord Healthcare Ltd
Mylan N.V.

Myelodysplastic Syndrome (MDS) Therapeutics Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Myelodysplastic Syndrome (MDS) Therapeutics Market

Myelodysplastic Syndrome (MDS) Therapeutics Market

The global Myelodysplastic Syndrome (MDS) Therapeutics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Myelodysplastic Syndrome (MDS) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Myelodysplastic Syndrome (MDS) Therapeutics.

Report Scope

The Myelodysplastic Syndrome (MDS) Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Myelodysplastic Syndrome (MDS) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Myelodysplastic Syndrome (MDS) Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Myelodysplastic Syndrome (MDS) Therapeutics Market Report

Report Metric Details
Report Name Myelodysplastic Syndrome (MDS) Therapeutics Market
CAGR 5%
Segment by Type
Segment by Application
  • In-Patient
  • Out-Patient
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Novartis AG, Celgene Corporation, Otsuka Pharmaceutical Co., Ltd., Sandoz Inc., Dr Reddys Laboratories Limited, Pharmascience Inc., Accord Healthcare Ltd, Mylan N.V.
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Myelodysplastic Syndrome (MDS) Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Myelodysplastic Syndrome (MDS) Therapeutics Market report?

Ans: The main players in the Myelodysplastic Syndrome (MDS) Therapeutics Market are Novartis AG, Celgene Corporation, Otsuka Pharmaceutical Co., Ltd., Sandoz Inc., Dr Reddys Laboratories Limited, Pharmascience Inc., Accord Healthcare Ltd, Mylan N.V.

What are the Application segmentation covered in the Myelodysplastic Syndrome (MDS) Therapeutics Market report?

Ans: The Applications covered in the Myelodysplastic Syndrome (MDS) Therapeutics Market report are In-Patient, Out-Patient

What are the Type segmentation covered in the Myelodysplastic Syndrome (MDS) Therapeutics Market report?

Ans: The Types covered in the Myelodysplastic Syndrome (MDS) Therapeutics Market report are Azacitidine, Lenalidomide, Decitabine, Deferasirox, Others

Recommended Reports

Rare Disease Therapeutics

Cancer & Oncology Treatments

Neurology & Mental Health

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Azacitidine
1.2.3 Lenalidomide
1.2.4 Decitabine
1.2.5 Deferasirox
1.2.6 Others
1.3 Market by Application
1.3.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 In-Patient
1.3.3 Out-Patient
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Perspective (2019-2030)
2.2 Myelodysplastic Syndrome (MDS) Therapeutics Growth Trends by Region
2.2.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Myelodysplastic Syndrome (MDS) Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Myelodysplastic Syndrome (MDS) Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Myelodysplastic Syndrome (MDS) Therapeutics Market Dynamics
2.3.1 Myelodysplastic Syndrome (MDS) Therapeutics Industry Trends
2.3.2 Myelodysplastic Syndrome (MDS) Therapeutics Market Drivers
2.3.3 Myelodysplastic Syndrome (MDS) Therapeutics Market Challenges
2.3.4 Myelodysplastic Syndrome (MDS) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Myelodysplastic Syndrome (MDS) Therapeutics Players by Revenue
3.1.1 Global Top Myelodysplastic Syndrome (MDS) Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Myelodysplastic Syndrome (MDS) Therapeutics Revenue
3.4 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Concentration Ratio
3.4.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Myelodysplastic Syndrome (MDS) Therapeutics Revenue in 2023
3.5 Myelodysplastic Syndrome (MDS) Therapeutics Key Players Head office and Area Served
3.6 Key Players Myelodysplastic Syndrome (MDS) Therapeutics Product Solution and Service
3.7 Date of Enter into Myelodysplastic Syndrome (MDS) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Myelodysplastic Syndrome (MDS) Therapeutics Breakdown Data by Type
4.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Forecasted Market Size by Type (2025-2030)
5 Myelodysplastic Syndrome (MDS) Therapeutics Breakdown Data by Application
5.1 Global Myelodysplastic Syndrome (MDS) Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Myelodysplastic Syndrome (MDS) Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size (2019-2030)
6.2 North America Myelodysplastic Syndrome (MDS) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2019-2024)
6.4 North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size (2019-2030)
7.2 Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2019-2024)
7.4 Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Size (2019-2030)
9.2 Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis AG
11.1.1 Novartis AG Company Detail
11.1.2 Novartis AG Business Overview
11.1.3 Novartis AG Myelodysplastic Syndrome (MDS) Therapeutics Introduction
11.1.4 Novartis AG Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2019-2024)
11.1.5 Novartis AG Recent Development
11.2 Celgene Corporation
11.2.1 Celgene Corporation Company Detail
11.2.2 Celgene Corporation Business Overview
11.2.3 Celgene Corporation Myelodysplastic Syndrome (MDS) Therapeutics Introduction
11.2.4 Celgene Corporation Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2019-2024)
11.2.5 Celgene Corporation Recent Development
11.3 Otsuka Pharmaceutical Co., Ltd.
11.3.1 Otsuka Pharmaceutical Co., Ltd. Company Detail
11.3.2 Otsuka Pharmaceutical Co., Ltd. Business Overview
11.3.3 Otsuka Pharmaceutical Co., Ltd. Myelodysplastic Syndrome (MDS) Therapeutics Introduction
11.3.4 Otsuka Pharmaceutical Co., Ltd. Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2019-2024)
11.3.5 Otsuka Pharmaceutical Co., Ltd. Recent Development
11.4 Sandoz Inc.
11.4.1 Sandoz Inc. Company Detail
11.4.2 Sandoz Inc. Business Overview
11.4.3 Sandoz Inc. Myelodysplastic Syndrome (MDS) Therapeutics Introduction
11.4.4 Sandoz Inc. Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2019-2024)
11.4.5 Sandoz Inc. Recent Development
11.5 Dr Reddys Laboratories Limited
11.5.1 Dr Reddys Laboratories Limited Company Detail
11.5.2 Dr Reddys Laboratories Limited Business Overview
11.5.3 Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Therapeutics Introduction
11.5.4 Dr Reddys Laboratories Limited Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2019-2024)
11.5.5 Dr Reddys Laboratories Limited Recent Development
11.6 Pharmascience Inc.
11.6.1 Pharmascience Inc. Company Detail
11.6.2 Pharmascience Inc. Business Overview
11.6.3 Pharmascience Inc. Myelodysplastic Syndrome (MDS) Therapeutics Introduction
11.6.4 Pharmascience Inc. Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2019-2024)
11.6.5 Pharmascience Inc. Recent Development
11.7 Accord Healthcare Ltd
11.7.1 Accord Healthcare Ltd Company Detail
11.7.2 Accord Healthcare Ltd Business Overview
11.7.3 Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Therapeutics Introduction
11.7.4 Accord Healthcare Ltd Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2019-2024)
11.7.5 Accord Healthcare Ltd Recent Development
11.8 Mylan N.V.
11.8.1 Mylan N.V. Company Detail
11.8.2 Mylan N.V. Business Overview
11.8.3 Mylan N.V. Myelodysplastic Syndrome (MDS) Therapeutics Introduction
11.8.4 Mylan N.V. Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2019-2024)
11.8.5 Mylan N.V. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
FEATURED COMPANIES
Novartis
Celgene Corporation
Otsuka Pharmaceutical Co Ltd
Sandoz Inc
Dr Reddys Laboratories Limited
Pharmascience
Accord Healthcare Ltd
Mylan N.V.
List of Tables
    Table 1. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
    Table 2. Key Players of Azacitidine
    Table 3. Key Players of Lenalidomide
    Table 4. Key Players of Decitabine
    Table 5. Key Players of Deferasirox
    Table 6. Key Players of Others
    Table 7. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
    Table 8. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 9. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Region (2019-2024) & (US$ Million)
    Table 10. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Region (2019-2024)
    Table 11. Global Myelodysplastic Syndrome (MDS) Therapeutics Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 12. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Region (2025-2030)
    Table 13. Myelodysplastic Syndrome (MDS) Therapeutics Market Trends
    Table 14. Myelodysplastic Syndrome (MDS) Therapeutics Market Drivers
    Table 15. Myelodysplastic Syndrome (MDS) Therapeutics Market Challenges
    Table 16. Myelodysplastic Syndrome (MDS) Therapeutics Market Restraints
    Table 17. Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue by Players (2019-2024) & (US$ Million)
    Table 18. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Players (2019-2024)
    Table 19. Global Top Myelodysplastic Syndrome (MDS) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myelodysplastic Syndrome (MDS) Therapeutics as of 2023)
    Table 20. Ranking of Global Top Myelodysplastic Syndrome (MDS) Therapeutics Companies by Revenue (US$ Million) in 2023
    Table 21. Global 5 Largest Players Market Share by Myelodysplastic Syndrome (MDS) Therapeutics Revenue (CR5 and HHI) & (2019-2024)
    Table 22. Key Players Headquarters and Area Served
    Table 23. Key Players Myelodysplastic Syndrome (MDS) Therapeutics Product Solution and Service
    Table 24. Date of Enter into Myelodysplastic Syndrome (MDS) Therapeutics Market
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Type (2019-2024) & (US$ Million)
    Table 27. Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share by Type (2019-2024)
    Table 28. Global Myelodysplastic Syndrome (MDS) Therapeutics Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 29. Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share by Type (2025-2030)
    Table 30. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Application (2019-2024) & (US$ Million)
    Table 31. Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share by Application (2019-2024)
    Table 32. Global Myelodysplastic Syndrome (MDS) Therapeutics Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 33. Global Myelodysplastic Syndrome (MDS) Therapeutics Revenue Market Share by Application (2025-2030)
    Table 34. North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 35. North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 36. North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 37. Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 38. Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 39. Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 40. Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 41. Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Region (2019-2024) & (US$ Million)
    Table 42. Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Region (2025-2030) & (US$ Million)
    Table 43. Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 44. Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 45. Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 46. Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 47. Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2019-2024) & (US$ Million)
    Table 48. Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Size by Country (2025-2030) & (US$ Million)
    Table 49. Novartis AG Company Detail
    Table 50. Novartis AG Business Overview
    Table 51. Novartis AG Myelodysplastic Syndrome (MDS) Therapeutics Product
    Table 52. Novartis AG Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2019-2024) & (US$ Million)
    Table 53. Novartis AG Recent Development
    Table 54. Celgene Corporation Company Detail
    Table 55. Celgene Corporation Business Overview
    Table 56. Celgene Corporation Myelodysplastic Syndrome (MDS) Therapeutics Product
    Table 57. Celgene Corporation Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2019-2024) & (US$ Million)
    Table 58. Celgene Corporation Recent Development
    Table 59. Otsuka Pharmaceutical Co., Ltd. Company Detail
    Table 60. Otsuka Pharmaceutical Co., Ltd. Business Overview
    Table 61. Otsuka Pharmaceutical Co., Ltd. Myelodysplastic Syndrome (MDS) Therapeutics Product
    Table 62. Otsuka Pharmaceutical Co., Ltd. Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2019-2024) & (US$ Million)
    Table 63. Otsuka Pharmaceutical Co., Ltd. Recent Development
    Table 64. Sandoz Inc. Company Detail
    Table 65. Sandoz Inc. Business Overview
    Table 66. Sandoz Inc. Myelodysplastic Syndrome (MDS) Therapeutics Product
    Table 67. Sandoz Inc. Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2019-2024) & (US$ Million)
    Table 68. Sandoz Inc. Recent Development
    Table 69. Dr Reddys Laboratories Limited Company Detail
    Table 70. Dr Reddys Laboratories Limited Business Overview
    Table 71. Dr Reddys Laboratories Limited Myelodysplastic Syndrome (MDS) Therapeutics Product
    Table 72. Dr Reddys Laboratories Limited Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2019-2024) & (US$ Million)
    Table 73. Dr Reddys Laboratories Limited Recent Development
    Table 74. Pharmascience Inc. Company Detail
    Table 75. Pharmascience Inc. Business Overview
    Table 76. Pharmascience Inc. Myelodysplastic Syndrome (MDS) Therapeutics Product
    Table 77. Pharmascience Inc. Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2019-2024) & (US$ Million)
    Table 78. Pharmascience Inc. Recent Development
    Table 79. Accord Healthcare Ltd Company Detail
    Table 80. Accord Healthcare Ltd Business Overview
    Table 81. Accord Healthcare Ltd Myelodysplastic Syndrome (MDS) Therapeutics Product
    Table 82. Accord Healthcare Ltd Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2019-2024) & (US$ Million)
    Table 83. Accord Healthcare Ltd Recent Development
    Table 84. Mylan N.V. Company Detail
    Table 85. Mylan N.V. Business Overview
    Table 86. Mylan N.V. Myelodysplastic Syndrome (MDS) Therapeutics Product
    Table 87. Mylan N.V. Revenue in Myelodysplastic Syndrome (MDS) Therapeutics Business (2019-2024) & (US$ Million)
    Table 88. Mylan N.V. Recent Development
    Table 89. Research Programs/Design for This Report
    Table 90. Key Data Information from Secondary Sources
    Table 91. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size Comparison by Type (2024-2030) & (US$ Million)
    Figure 2. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Type: 2023 VS 2030
    Figure 3. Azacitidine Features
    Figure 4. Lenalidomide Features
    Figure 5. Decitabine Features
    Figure 6. Deferasirox Features
    Figure 7. Others Features
    Figure 8. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size Comparison by Application (2024-2030) & (US$ Million)
    Figure 9. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Application: 2023 VS 2030
    Figure 10. In-Patient Case Studies
    Figure 11. Out-Patient Case Studies
    Figure 12. Myelodysplastic Syndrome (MDS) Therapeutics Report Years Considered
    Figure 13. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 14. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 15. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Region: 2023 VS 2030
    Figure 16. Global Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Players in 2023
    Figure 17. Global Top Myelodysplastic Syndrome (MDS) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myelodysplastic Syndrome (MDS) Therapeutics as of 2023)
    Figure 18. The Top 10 and 5 Players Market Share by Myelodysplastic Syndrome (MDS) Therapeutics Revenue in 2023
    Figure 19. North America Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 20. North America Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Country (2019-2030)
    Figure 21. United States Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 22. Canada Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 23. Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 24. Europe Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Country (2019-2030)
    Figure 25. Germany Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 26. France Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 27. U.K. Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 28. Italy Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. Russia Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. Nordic Countries Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. Asia-Pacific Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Region (2019-2030)
    Figure 33. China Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 34. Japan Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. South Korea Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. Southeast Asia Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 37. India Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 38. Australia Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 39. Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 40. Latin America Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Country (2019-2030)
    Figure 41. Mexico Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 42. Brazil Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 43. Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. Middle East & Africa Myelodysplastic Syndrome (MDS) Therapeutics Market Share by Country (2019-2030)
    Figure 45. Turkey Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. Saudi Arabia Myelodysplastic Syndrome (MDS) Therapeutics Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 47. Novartis AG Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Therapeutics Business (2019-2024)
    Figure 48. Celgene Corporation Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Therapeutics Business (2019-2024)
    Figure 49. Otsuka Pharmaceutical Co., Ltd. Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Therapeutics Business (2019-2024)
    Figure 50. Sandoz Inc. Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Therapeutics Business (2019-2024)
    Figure 51. Dr Reddys Laboratories Limited Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Therapeutics Business (2019-2024)
    Figure 52. Pharmascience Inc. Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Therapeutics Business (2019-2024)
    Figure 53. Accord Healthcare Ltd Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Therapeutics Business (2019-2024)
    Figure 54. Mylan N.V. Revenue Growth Rate in Myelodysplastic Syndrome (MDS) Therapeutics Business (2019-2024)
    Figure 55. Bottom-up and Top-down Approaches for This Report
    Figure 56. Data Triangulation
    Figure 57. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

Global Myelodysplastic Syndrome Drug Market Research Report 2025
Global Myelodysplastic Syndrome Treatment Market Research Report 2024
Myeloid Cells Targeting Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Depression MDD Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Hematological Malignancies Disease Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Anemia Therapeutic Drugs Market Research Report 2024
Global Hematological Malignancy Treatment Market Research Report 2025
Global Antipsychotic Drug Market Research Report 2024
Cancer Stem Cell Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Spine Disorders Treatment Market Research Report 2024
Hematological Malignancies Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Sickle Cell Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Acute Myeloid Leukemia AML Therapeutics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Musculoskeletal Disorders Therapeutics Market Research Report 2025
Hematological Malignancy Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Targeted Drugs for Multiple Myeloma Market Research Report 2024
Global Myelodysplastic Syndrome Market Research Report 2024
Global Critical Care Therapeutics Market Research Report 2025
Global Prostate Cancer Diagnostics and Therapy Market Research Report 2024
Global Neutropenia Drugs Market Research Report 2025
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions